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S_ry A 95 kDa membrane protein (P-95) has been previously noted to be overexpr in a
doxorubicin-resistant subie of the MCF-7 breast cancer line and in cinical samples obtained from patients
with soLid tumours refractory to doxorubcin. We performed Western blotting on blast cell lysates from adults
with acute myeloid Leukacmia, using antsera to P-95. Concomitant flow cytometnc assays measured
daunorubicin accumulaton and retention. Blasts from 16/46 patient samples had detectable P-95 and had
reded accumulation of daunorubici compared with the negative marrows. Experiments with the P-95
positive MCF-7 multidrug-resistant subhe demonstrated d d daunorubicin accumulation and retention
relative to the sensitive parent ine. AML blast cells postiv for P-95 also demonstratqd greater overal in vitro
survival in the presence of daunorubicin relative to the P-95-negtive samples. The expression of P-95 did not
correlate with failure to achieve an initial complete missionwith daunorubicin and cytarabine induction
chemotherapy. We conclude that the P-95 proten may possess an efftux transporter function, and may
represent another anism responsible for anthracycine resistance in acute myeloid kleuaemia
Keyworq multidrug resistance; anthracydine; protein; acute myeloid leukaemia
The development of drug resistance in leukaemia cells con-
stitutes the major reason for treatment failure in patients
with acute myeloid leukaemia (AML). The mainstays of
treatment of AML are the antimetabolite cytarabine and a
variety of natural product drugs, including the anthracycline
daunorubicin (dnr), the anthraquinone mitoxantrone and the
epipodophyllotoxin etoposide. During the past decade, cellu-
lar resistance to a broad spectrum of unrelated natural
cytotoxins has been described in leukaemia and other neo-
plasms and has been termed multidrug resistance (MDR)
(Rothenburg and Ling, 1989). The classic pattern of MDR
has been associated with the overexpression ofP-glycoprotein
(Pgp), the 170 kDa product of the MDR] gene (Juliano and
Ling, 1976). Pgp is thought to function as an energy-
dependent efflux pump for a variety of molecules, including
certain chemotherapeutic agents (Fojo et al., 1985).
The role of Pgp in mediating MDR in leukaemia remains
unclear. Several studies, using slot-blot hybridisation for
mdrl message, or immunohistochemical or flow cytometric
detection of Pgp with the MRK16 or C219 monoclonal
antibodi, have found a high frequency (>30% of patient
samples) of reactivity with these probes in AML blasts at the
time of presentation (Sato et al., 1990; Marie et al., 1991).
Other studies, including our own, found a low frequency of
MDR] expression in AML cells from previously untreated
patients (Ito et al., 1989; Kato et al., 1991; Ross et al., 1993).
In another series of 56 patients, no detectable Pgp was
observed by filter hybridisation, whereas 27 of the 51 had a
low level expression of MDR] detected by reverse transcrip-
tase-polymerase chain reaction (Noonan et al., 1991). These
low levels of MDRJ expression did not correlate with the
clinical response of the leukaemia patients to
chemotherapy.
We have noted variability of dnr uptake and retention in
leukaemic blast cells from different patients. In our studies,
the MDR modulators cyclosporin A (CsA) and verapamil
caused statistically significant enhancement of dnr accumula-
tion, retention and cytotoxicity in more than half of marrow
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specimens from previously untreated AML patients (Ross et
al., 1993). The results of these functional assays for
facilitated dnr export contrast with our observation of detec-
table Pgp expression in less than 10% of our AML bone
marrow samples using a sensitive Western blot assay (Ross et
al., 1993). This discrepancy between the presence of a drug
efflux pump and the absence of detectable Pgp suggests that
other anisMs of drug efflux may be present.
In addition to Pgp, recent studies suggest that other cell-
surface proteins might contribute to MDR in certain cell
types (Marquardt et al., 1990; Cole et al., 1992). A novel
95 kDa MDR-associated membrane protein, termed P-95,
has been reported to be overexpressed in MCF-7 breast
cancer cells selected for resistance to doxorubicin in the
presence ofverapamiL in order to inhibit the development of
Pgp overexpression (Chen et al., 1990). The resistant subline,
termed MCF-7/AdrVp, does not express Pgp, and is highly
resistant to anthracyclines, melphalan and VM-26, but not
vinblastine. Glutathione content and the activity ofthe gluta-
thione transferases were not alterd and depletion of gluta-
thione with buthionine sulphoxime did not affect drug resis-
tance. Prolonged culture of MCF-7/AdrVp cells in drug-free
medium led to the development of drug-sensitive revertants,
which were noted to have greatly diminished expression of
P-95. Immunohistochemical and indirect immunofluorescence
experiments demonstrated localisation of the P-95 protein on
the cell surface, and the protein was enriched in detergent-
solubiised membrane fractions of MCF-7/AdrVp. The
demonstration of P-95 protein in biopsy specimens from
solid tumour patients refractory to chemotherapy suggested
that the protein might play a role in clinical drug resistance
(Chen et al., 1990).
We recently reported that P-95 was highly expressed in two
human small-cell lung cancer cell lines, NCI-H1688 and NCI-
H660, that displayed intrinsic multidrug resistance (Doyle et
al., 1993). These cell lines do not overexpress Pgp or the
recently described multidrug resistance protein (MRP), and
have an atypical pattern ofdrug resistance (Cole et al., 1992;
Doyle et al., 1993). We now report studies of P-95 immuno-
reactivity by Western blotting on blast cells from AML
patients. The expression of P-95 was correlated with the
accumulation, retention and cytotoxicity of dnr by leukaemia
cells.A.*hsdaimi chImrsdm pr.h -
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Materials
Verapamil hydrochloride, from Abbott Labs (Chicago, IL,
USA), was obtained as a stock solution of 2.5mgml-' in
0.85% saline. Cyclosporin A was obtained as Sandimmune
Injectable from the Sandoz Corporation (East Hanover, NJ,
USA) as a stock solution of 50mgml-' dissolved in a mix-
ture of 32.9% ethanol in Cremophor EL. Daunorubicin was
obtained from Wyeth Laboratories (Philadelphia, PA,
USA).
Cell culture
The human small-cell lung cancer cell line NCI-H1688 was
obtained from the NCI-Navy Medical Oncology Branch
(Betheda, MD, USA). The NCI-H1688 line was cultured in
RPMI-1640 medium supplemented with 2mM L-glu
and 10% fetal bovine serum (Gibco, Grand Island, NY,
USA). The leukaemia cell line HL-60 was cultured in RPMI-
1640 medium with 10% fetal bovine serum, 1% non-essential
amino acids and 1% sodium pyruvate. The MCF-7 breast
cancer cell line and the doxorubicin-resistant subline MCF-7/
AdrVp were maintained in Iscove's modification of Eagle's
medium (IMEM) with 25 ig ml gentamici 2 mM L-
glutamine (Biofluids, Rockville, MD, USA) and 10% fetal
bovine serum. The MCF-7/AdrVp subline was cultured con-
tinuously in lOOngml-l doxorubicin and 5pgml-l
verapamil until 5-10 days before the experiments were per-
formed.
Marrow collection andpreparation
All 39 patients studied had the diagnosis of AML established
on the basis of microscopic examination of Wright's-stained
specimens of bone marrow, with French-American-British
(FAB) subcategorisation established by histochemical stains.
lThe AML patients had a median age of 59 (range 19-80)
and a typical FAB distribution. The 39 patients included 17
femals and 22 males. The marrow was diluted 1:1 with
RPMI-1640 medium, and 5 ml ofFicoll-Hypaque was layer-
ed under the marrow suspension. Mononuclear cells were
collected at the Ficoll-Hypaque (specific gravity 1.077) and
medium interface after centrifugation (400g for 40min). The
mononuclear cells were washed and counted. The percentage
of blast cells in the specimens was greater than 90% in
almost all samples.
The dnr accumulation, retention and cytotoxicity results
from 18 of the 46 marrow specimens have been recently
reported (Ross et al., 1993). In this paper, we compare the
results of these studies with the expression of the P-95 pro-
tein in AML blast samples.
Western blot analysis
Rabbit polyclonal antibodies against the P-95 protein were
prePared as previously described (Halligan et al., 1985). The
95 kDa band was identified by saining detergent-solubilised
MCF-7/AdrVp membrane proteins separated on SDS-
PAGE geLs. The band was excised from the gel, soaked in
water overnight and then lyophiised. The lyophilsed gel was
mixed with Freund's adjuvant for immunisation as previously
described (Hwang et al., 1989).
Approximately 2 x 107 cells from each bone marrow sam-
ple were resuspended by sonication in an alkylation buffer
containing 6 M guanidine hydrochloride, 1% (v/v) 2-mer-
captoethanol, 1mMPMSF, 10 mmEDTA and 250 mMTris-
HCI, pH 8.5, and stored at -80-C. At the time samples were
thawed, iodoacetamide was added to the solubilised protein
to a final concentration of 150 mM. After a 1h incubation in
the dark, alkylation was stopped with 2-mercaptoethanol at
1% (v/v). The samples were subsequentially dialysed at 4-C against 4 M deionised urea (four changes, 90min each) and
0.1% SDS (three changes, 90 mineach), lyophilised to dry-
ness and solubilised in SDS sample buffer (4 M urea/2%
SDS/62.5 mM Tris-HCI, pH 6.8/1 mM EDTA, 0.002%
bromphenol blue) at a concentration of 5 x I0 cells IOl-1.
Samples were heated to 70-C for 20min, loaded onto lanes
of a 3% stacking gel, and separated by SDS-PAGE on a
5-15% gradient gel. The proteins were transferred to nitro-
cellulose in Towbin buffer at 20 V for 60min (Towbin et al.,
1979). The blots were dried for 2 h then incubated with TSM
buffer (150mm sodium chloride, 10 mM Tris-HCI, pH 7.4,
5% powdered milk, lOOUml- penicillin, lOO&gml-
streptomycin, I mM sodium azide) for 6-12 h at room
temperature. After washing four times with TS buffer
(150 mM sodium chloride, 10 mM Tris-HCI, pH 7.4) the
blots were incubated for 12-15 h at room temperature, ug
an appropriate dilution of rabbit anti-P-95 antisera in TSM
buffer. The blots were washed three times with TS buffer
containing 2 M urea and 0.05% NP-40, and once in TS buffer
alone. The blots were then incubated in TSM buffer contain-
ing 5-1O i Ci of "NI-labelled goat anti-rabbit IgG (Amer-
sham, Arlington Heights, IL, USA) for 90min. The wash
procedure was repeated and the blots were exposed to film at
-70(C.
Western blots were also performed on AML blast lysates
with C219, a monoclonal antibody reactive with Pgp (Kart-
ner et al., 1985). These blots included lanes for the cassic
MDR cell line, DC3F/ADX, and its parent drug-sensitive cell
line, DC3F (Scotto et al., 1986). A different membrane
preparation was used for these Western blots to optimise for
Pgp detection, as previously described (Ross et al., 1993).
AML blast cells from each sample were placed in lyss buffer
(0.01 M Tris, pH 7.4, 10mM potassium chloride, 1.5 mM
magnesium chloride, 2 mM amino acetonitrile and 2 mM
PMSF), and homogenised with a Dounce homogeniser. After
a low-speed centrifugation to remove nuclei, the cellular
membranes were collected by ultracentrifugation (100,000g,
30min). The purified membranes (50 agpergel lane) were
subjected to SDS-PAGE, blotted and probed with C219 as
previously described (Ross et al., 1993).
Daunorubicin accwnuation andretention studies
These studies were performed solely from patients at our
institution, as previously described (Ross et al., 1993). AML
blast cells, from 46 marrow specmens, were exposed in
culture (RPMI-1640 medium, 10% fetal calf serum, pH 7.2)
to dnr (1 &gml-') for 3h, which we have noted was the time
required for blast cells to achieve intracellular steady-state
levels of dnr (Ross et al., 1986). All dnr accumulation and
retention studies were initiated on the same day as the bone
marrow aspiration of the AML blasts. The resistance modu-
lators verapamil (6.6 ILM) or cylosporin A (5gm) were added
to fractions of most AML blast samples. Extracellular drugs
were removed by washing in phosphate-buffered saline (PBS)
at 4C and half of each sample was tested im iately for
dnr accumulation. The other halfofeach sample was washed
and placed in pe med culture medium for 16 h, in an
incubator with 5% carbon dioxide, after which the retention
of intracellular dnr was measured in the presence or absence
of the MDR modulators noted above. Intracellular dnr con-
tent was quantified by flow cytometry (FACStar Plus flow
cytometer, Becton Dickinson, San Jose, CA, USA), using
laser excitation of 488 nm, and reading fluorescence emission
with the use of a 575-25 um filter. Logarithmic amplification
of red fluorescence signals was used throughout. Fluorescent
bead standards were used to ensure precise reproducibility of
fluoresence mesurements. Cell sorting was used in all cases
to determine the scatter gate that containd leukaemic blast
cells. The relative intracellular dnr content was obtained by
dividing the channel number that represented the mean red
fluorescence for that sample by 256 (the number of channels
per log decade), then obtaining the antilog of this value.
Breast cancer cellsublines, MCF-7 and MCF-7/AdrVp, were
trypsinised (0.25% trypsin, 1mm EDTA, Gibco) for 5 minat
3rC, then washedjust before the flow cytometric analysis.
This trypsinisation procedure did not alter dnr accumulationA ~~~~A a mdm bcbu1-- ist p,eOW
14 ~~~~~~~~~~~~~LA Dqe eta
or retention studies in free-floating HL-60 or HL-60/Vinc
(MDR) cells, and was observed to create a single-cell suspen-
sion in the breast cancer sublines.
Cytotoxicity studies
Forty patient blast cell samples were studied. Blast cells were
placed in RPMI culture medium, with or without dnr and/or
the reistance modulators. The cultures were incubated for
between 48 and 120h, in various experiments, in the con-
tinuous presence of drugs, after which the number of viable
cells per ml of culture was determined by the use of
fluorescein diacetate (FDA) and propidium iodide (PI), as
described below. During this short-term culture of AML
blast cells, viable cell number decreased to a mean of45% of
the original cell inoculum (median 38%, range 1-119%) in
control cultures (no drug added).
A sensitive flow cytometric method that we had developed
for determining the number of cells surviving in suspension
culture was used (Ross et al., 1986). Briefly, at the ime of
determination of the number of surviving viable cells in
culture, FDA and PI in isotonic solution were added to the
cells in culture, to achieve final concentrations of 0.5 and
50 tgml-' respectively. Viable cells were identified as those
that displayed a bright-green fluorescence, induced by the
intracellular metabolism of fluorscein diacetate to
fluorescein, and a low-red fluorescence, indicating cellular
exclusion of PI. The number of viable cells per ml of culture
medium sample was determined by a timed count and
knowledge of the flow cytometer sample flow rate, as
previously described (Ross et al., 1986).
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Fugwe I Immunoblotting of AML blast lysates with antisera
derived against gel-purified P-95 protein. Serial dilutions of the
drug-sensitive kukaemia cel lne HL-60 were used as a negative
control for P-95 imunoblotting. Fifty micrograms of protein
from indiviual AML lysates was loaded in each lane. Two
dilutions of the multidrug-resistant, Pgp-negative snall-cell lung
cancer cell line NCI-H1688 (50 and 25gg) was used as the
positive control. STD is the molecular weight standard lane.
three had marrow blasts with detectable P-95. Among the
total 39 AML patients studied, no FAB subtype or cyto-
genetic abnormality correlated with P-95 expression.
Statistical analysis
Correlation of P-95 expression with dnr accumulation and
retention, and with dnr cytotoxicity, was performed using a
Mann-Whitney test. The effect of a resistance modulator,
based on 3 h accumulation and/or 16 h retention of dnr, was
defined as the percentage change in dnr accumulation or
retention, and caculated as previously reported (Ross et al.,
1993). Similar criteria were used to measue the effect of
resistance modulators on dnr cytotoxicity in vitro.
Resus
Western blottingfor P-95
Western blotting was performed on 46 blast cell lysates from
39 adult patients with AML usng specific antisera to the
P-95 protein. In each P-95 Western blot, the MDR human
smalcl lung cancer cell line NCI-H1688, which highly
expresses P-95, was used as a postive control (Doyle et al.,
1993). The drug-sensitive HL-60 cell line was used on each
blot as a negative control. Sixteen of the 46 marrow speci-
mens had clearly detectable expression of P-95 by Western
blotting. A representative Western blot with positive and
negative AML samples is demonstrated in Figure 1. In this
blot, we considered patient sample MR, AM, FR, GP and
LT to be positive for P-95 expression.
Twenty-nine patients were tudied at the time ofdiagnosis,
ofwhich 10/29 (34%) were P-95 positive. Seven bone marrow
samples from six of these patients were also obtained at
relapse. Of the six patients with marrows obtained both at
diagnosis and after treatment, two demonstrated P-95 expres-
sion to be increased in the relapsed specimen relative to the
initial marrow sample. For example, one patient (MR) had
undetectable P-95 expression at diagosis (Figure 1, lane 16
from left), but had readily detectable expresson of the pro-
tein at different relapse marrows (Figure 1, lanes 6 and 12).
In the other four paired specimens, P-95 expression was
essentially unchanged between the times of diagnosis and
relapse.
Ten AML patients had samples obtained for P-95 studies
only at the time of relapse. Of these ten relapsed patients,
Correlation ofP-95 Western blotting with dnr accwnulation
andretention
Concomitant flow cytometric assays measuring 3 h accumu-
lation of dnr (1 jigml-') were performed on AML blast cells
from the 46 patient marrows used for P-95 Western blotting.
Sixteen of these 46 samples were positive for P-95 expression
by Western blotting. Thirty-seven of the 46 samples also had
flow cytometric assays of dnr retention performed 16 h after
washing the blast samples free of extracellular drug. Of the
37 marrow samples tested for dnr retention, 13 were positive
for P-95 by Western blotting.
The P-95-positive marrows had reduced accumulation of
dnr relative to the negative marrows (Figure 2). The differ-
ence was statistically significant using a Mann-Whitney test,
with P = 0.033. Only one ofthe P-95-positive samples had an
accumulation value greater than the median of the P-95-
negative samples. A trend was also noted for decreased dnr
retention in the P-95-positive marrows (Figure 2), with
P= 0.067. There were no P-95-positive samples with high
retention of daunorubicin.
All of the AML marrows described above had dnr accum-
ulation and retention measurements performed with or with-
out the addition of 5giM cyclosporin A. Forty-three samples
(27 P-95-negative, 16 P-95-positive) also had dnr accumula-
tion experiments performed with or without the addition of
6.6pM verapamil. Thirty-four samples (21 P-95-negative and
13 P-95-positive) had dnr retention experiments performed
with or without verapamil. No significnt difference between
the P-95-positive and -negative groups with respect to the
percentage e nt of dnr accumulation or retention by
verapamil or cyclosporin A was noted. This was true for the
whole group, as well as for the subset of samples from
previously untreated AML patients. Verapamil or cyclo-
sporin A caused a greater than 20% enhancement of dnr
accumulation in more than 25% and 50% of these patients
respectively; however, this enhancement did not correlate
with P-95 status.
Dnr acwmdation and retention in breast cancer sublines
To examine further the association between P-95 expression
and facilitated export ofdnr, we performed dnr accumulationAccumulation
0)
0
c
0)
C.) 0)
~0
Cu
'a
3,000
2,500
2,000
1,500
1,000
500
A P= 0.033
n = 30
A
AA
A
MA
A
*& A t
A
&AA
AA
AA
n= 16
A
A
A
A
A
MA
A
A
No Yes
Retention
P= 0.067
n= 24
±
AA
AA AA
AMA
AA
A"A
n= 13
A A
AAA
*l-
No Yes
Detectable P-95 expression
Figure 2 Correlation of dnr accumulation and retention, in
AML blast cells, with P-95 expression by immunoblotting. The
intracellular dnr content of the blast cells was quantitated by a
flow cytometric measurement of dnr fluorescence. The amount of
intracellular dnr accumulated immediately following a 3 h incuba-
tion with 1 gig ml dnr as well as the amount of drug retained
16 h after washing the cells free ofexternal drug were determined.
The median values for dnr accumulation and retention are shown
by horizontal bars.
and retention experiments in MCF-7 cells and in the MDR
subline MCF-7/AdrVp, which overexpresses P-95 (Figure 3).
An alteration in overall intracellular drug transport had not
been previously reported in MCF-7/AdrVp cells. Both cell
lines had measurements of dnr content for up to 3 h after
being placed in 1 gig ml1- of the drug. As shown in Figure 3,
the accumulation of dnr reached a plateau in both lines by
3 h, but the intracellular dnr content of the resistant MCF-7/
AdrVp cells was far less than that of the sensitive parent
cells. After washing the cells to remove extracellular dnr at
3 h, the retention of dnr at various time points was
measured. As shown in Figure 3, the P-95-positive MCF-7/
AdrVp cells rapidly lost almost all detectable dnr
fluorescence. The sensitive MCF-7 cells, starting from a
higher plateau of accumulated dnr, also showed a loss of dnr
fluorescence after washing the cells free of extracellular drug,
but the MCF-7 cells retain approximately 40% of the
accumulated dnr 2 h after the wash. The alteration in drug
accumulation observed was not due to differences in cell size
between the sensitive and drug-resistant sublines. Coulter
volumes were found to be 2,468 ± 116 gim3 for MCF-7/
AdrVp and 2,683 ± 100 iLm3 for MCF-7 cells.
A small but consistent enhancement of dnr accumulation
by cyclosporin A was noted in the P-95-positive MCF-7/
AdrVp subline (Figure 4). No enhancement ofdnr accumula-
tion by cyclosporin A was noted in the drug-sensitive MCF-7
parent line. The approximate 40% enhancement of dnr
accumulation was noted at 3 gM cyclosporin A, and was
maintained at concentrations between 3 and 30 gM.
Correlation ofP-95 expression with dnr cytotoxicity
Forty-one AML blast samples were examined for both P-95
expression and in vitro sensitivity to dnr. Western blot
analysis demonstrated 26 of these samples to be P-95
negative and 15 to be P-95 positive. No statistically signi-
ficant difference, overall, was found between P-95-positive
and P-95-negative samples with respect to dnr cytotoxicity
(Figure 5), although the difference in median cell survival
between P-95-positive and -negative samples exposed to
1.0 giM dnr reaches statistical significance, with P = 0.05.
The same 41 AML marrow specimens were also tested for
dnr cytotoxicity in the presence of 5 gM cyclosporin A or
6.6gLM verapamil. Greater than 40% enhancement of dnr cell
kiUing by either cyclosporin A or verapamil had previously
been observed in more than 60% of the samples studied
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Figure 3 Dnr accumulation and retention, measured in the P-95-
positive drug-resistant breast cancer subline, MCF-7/AdrVp (A),
and its drug-sensitive parental cell line MCF-7/W (X). Cells were
exposed to dnr (I gml mP') for varying periods of time. Flasks
were either assayed immediately for intracellular dnr content or
washed in ice-cold PBS and placed in a prewarmed culture
medium without dnr for varying times to measure the retention
ofthe drug. The cells were detached with trypsin and intracellular
dnr content was quantified by flow cytometry. The data points
represent the means of two different experiments. The veftical
bars represent the range.
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Figure 4 Percentage change in dnr accumulation in MCF-7/
AdrVP (0) and MCF-7 (U) cells by co-incubation with cyclo-
sporin A. Cells were exposed to dnr (1 fgml- ) with cyclosporin
A, at concentrations from 0 to 30pm, for 3 h Intracellular dnr
content was determined by flow cytometry, as described in the
Materials and methods section. The data shown represent the
means of two identical experiments, performed in triplicate on
different days. The vertical bars represent the range.
(Ross et al., 1993). No significant difference in enhancement
of dnr cytotoxicity with either modulator between the P-95-
positive and -negative groups was noted.
Western blottingfor Pgp
Thirty-four AML marrow lysates, from 25 patients, for
which P-95 Western blotting was performed, also had
immunoblotting performed for Pgp with the C219 mono-
clonal antibody (Ross et al., 1993). Nine patients were
studied twice. None of the 34 AML lysates had detectable
Pgp expression, although clearly positive expression ofPgp in
the DC3F/ADX multidrug-resistant control line was seen
with each blot (data not shown). A Pgp band was even noted
in the drug-sensitive parental DC3F cells, demonstrating the
sensitivity of the assay. Nine of these 25 patients had AML
u n T
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jF1e 5 Percentage of AML cells surviving vitro culture with
varying concentrations of dnr, analysed in relation to pression
of P-95. Each marrow sample was subdiided, and exposed to
either 0, 0.1, 0.3 or IOgu. dnr. The percentage of viable cels in
each group was calculated usin the FDA/PI flow cytomnric cell
survival assay, as described in the Mateials and methods sction.
The number of cells from each sample suriving with no dnr was
set at 100%. The horizontal bars denote the median percentage
of survival of P-95-positive and -negative AML samples at each
dnr concentration.
blasts positive for P-95. Among an additional 13 AML
lysates, for which P-95 was not tested, three samples had
detectable Pgp (Ross et al., 1993).
Association ofP-95 expression with clinical response
Of the 29 AML patients who were previously untreated with
cytotoxic chemotherapy, four patients with acute proganu-
locytic leukaemia were not evaluated for clinical response
because they were treated with all-trans retinoic acid. Of the
25 patients treated with daunorubicin (45 mgm-2 day-' for 3
days) and cytarabine (200mgm-2day-' for 7 days), 16 were
P-95 negative and nine were P-95 positive. Ten of the 16
P-95-negative patients (63%) and five of the nine P-95-
positive patients (56%) achieved complete remissions,
suggesting that P-95 expression and clical response are
independent (2 = 0.116, P = NS) in patients treated with the
combination of cytarabine and daunorubicin.
This exploratory study demonstrates that the surface mem-
brane-resident P-95 protein, originally found to be over-
expressed in breast cancer cells made resistant vitro to
doxorubicin, is present on and may be associated with lower
accumulation of dnr in leukaemic blast cells. This is not
hikely to be due to concurrent Pgp expression since only three
of the AML lysates from our overall cohort of 49 previously
untreated patients and 0/34 of our current samples had
detectable Pgp by Western blotting (Ross et al., 1993). The
MDR breast cancer subine, MCF-7/AdrVp, which overex-
presses P-95, also has decreased accumulation and retention
of dnr relative to the drug-sensitive parental cell line. This is
the first demonstration that P-95 is associated with altered
drug transport, both in the resistant cell line and in clinical
samples. These studies suggest that P-95 may have an efflux
transporter fumction and may represent another mechanism
responsible for anthracycline resistance in human neo-
plasms.
The MCF-7/AdrVp subline has previously been shown to
have no detectable mdrl transcription by Norther blotting
(Chen et al., 1990), and we have found that mdrl expression
in this line was undetectable by a reverse transcriptase-PCR
assay (data not shown). The MCF-7/AdrVp sublne has only
a minor decrease in topoisomerase H expression relative to
the MCF-7 parent line (Chen et al., 1990), and recent studies
have demonstrated that topoisomerase H expression in AML
blast cell specimens does not directly correlate with clinical
response to induction chemotherapy (Doyle et al., 1992;
Kaufinan et al., 1994). While expression of the P-95 mem-
brane protein has not been proven to cause low dnr accum-
ulation in MCF-7/AdrVp cells, it links this subline with a
subset of AML blast samples which similarly express P-95
and have low dnr accumulation.
AML cells expressing P-95 did not have greater enhance-
ment of anthracycline accumulation than P-95-negative sam-
ples after exposure to MDR modulators such as verapamil or
cyclosporin A. This is consistent with our finding that the
enhancement of dnr accumulation in the P-95-positive MCF-
7/AdrVp cells in response to CsA was relatively small com-
pared with classic Pgp-expressing cell lines such as HL-60/
Vinc, which in our studies had increases of up to 700% in
anthracycline accumulation and retention (Ross et al., 1993).
The blast cell accumulation and retention studies are consis-
tent with our in vitro cytotoxicity studies, which indicate that
AML blasts expressing P-95 have a trend towards greater
survival after exposure to daunorubicin, yet have no statis-
tically signifct enhancement of dnr cytotoxicity by
verapamil or CsA relative to P-95-negative cells.
A number of other membrane proteins have been associ-
ated with drug resistance. For example, an 85 kDa mem-
brane protein, identified by a monoclonal antibody MRK20,
has been reported as a marker for doxorubicin resistance
(Hamada et al., 1988). The cDNA encoding this protein has
recently been cloned and found to be identical to CD36, a
cell-surface adhesion molecule of endothelium, platelets and
monocytes (Sugimoto et al., 1993). Studies using the MRK20
antibody to examine the MCF-7/AdrVp cell line did not
detect expression of the 85 kDa protein (Chen et al., 1990).
Examination of the doxorubicin-resistant ovarian cell line
2780Ad, which expresses the 85 kDa protein, with antisera
against P-95 did not reveal any expression of the P-95
antigen (Chen et al., 1990). We have recently screened MCF-
7 and MCF-7/AdrVp cells with VM58, another monoclonal
antibody specific for CD36, using an indirect immunofluo-
rescenCe assay. Neither line was reactive with VM58, making
it unlikely that CD36 and P-95 are the same protein.
A Pgp-negative MDR leukaemia subline HL-60/Adr,
selected for resistance to doxorubicin, has been reported to
overexpress a 190-195 kDa membrane protein compared
with the sensitive parent ine (McGrath et al., 1989). This
protein is identical to the product of a gene amplified and
overexpressed in a MDR small-cell lung cancer subline
H69AR (Cole et al., 1992; Krishnamachary and Center,
1993). This recently cloned gene codes for a 190-195 kDa
protein termed the multidrug resistance-associated protein
(MRP). Sequence analysis reveals that MRP is a member of
the ATP-binding cassette (ABC) superfamily of transport
systems (Higgins et al., 1992). The relation of P-95 to MRP
in mediating non-Pgp MDR in leukaemia, lung cancer and
other neoplasms is unknown, although we find that P-95 is
not overexpressed in the HL60/Adr cell line, and reverse
transcriptase-PCR assays do not demonstrate MRP overex-
pression in the MCF-7/AdrVp cells (unpublished observa-
tion).
Bone marrow aspirates from two of our relapsing AML
patients demonstrated higher P-95 expression than did
aspirates from the same patients prior to chemotherapy.
These findings, coupled with the initial observation of P-95
expression in breast tumour recurrent after doxorubicin-
based chemotherapy, suggest that cancer cells expressing P-95
may be selected for in vivo by the administration of chemo-
therapy (Chen et al., 1990). While our study concentrated on
AML, we have found that three patients with acute lympho-
blastic leukaemia who had a poor response to induction
chemotherapy also expressed high levels of P-95 on their
lymphoblasts. We have recently found that membrane stain-
ing of P-95 protein can be detected by immunohistochemical
techniques in resistant lung cancer and breast cancer cells
which have been fixed in paraffm. The preservation of anti-A nove bleaemia dmo_esistae padein
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genic determinants of P-95 in fixed material should allow
screening of solid tumour specimens, to correlate P-95 ex-
pression with response to chemotherapy and patient sur-
vival.
The broad 95 kDa band detected by the antisera appears
to be a characteristic of the protein itself and not an artifact
of the electrophoretic technique. Rehybridisation of the blots
with antisera specific for topoisomerase II or actin revealed
the expected sharp bands (data not shown). Incubation of
NCI-H1688 cells in tunicamycin or cleavage of its membrane
proteins with Peptide N-glycosidase F (PNGase F) causes
diminution of the broad P-95 band and the appearance of a
sharp 35 kDa band reactive with anti-P-95 antisera (manu-
script in preparation). This 35 kDa band is presumably the
peptide core of the P-95 glycoprotein.
Lysates from the multidrug-resistant lung cancer line NCI-
H1688, hybridised with the P-95 antisera, also had a cross-
reacting high molecular weight bands of unknown signifi-
cance, as shown in Figure 1. This high molecular weight
band in NCI-H1688, but not MCF-7 AdrVp, is demonstrable
in three different antisera against P-95, generated against
either MCF-7 AdrVp or NCI-H1688 membranes. The high
molecular weight protein does not appear to be P-glyco-
protein or MRP since the genes encoding these proteins are
not detectably overexpressed in NCI-H1688 or MCF-7
AdrVp cells by reverse transcriptase PCR assays. A lack of
total specificity of the P-95 antisera is not surprising, since
the gel-purified 95 kDa band is the best current immunogen.
but the 95 kDa band by Western blotting can reliably distin-
guish the drug-resistant cell lines NCI-H1688 and MCF-7
AdrVp from drug-sensitive MCF-7 cells.
In AML, at present, we have not seen an obvious correla-
tion between P-95 expression and clinical response to initial
induction chemotherapy, but this may be because of the
small number of patients, tumour heterogeneity, the contri-
bution of cytarabine to the regimen and the possible contri-
bution of other mechanisms of resistance such as those
described above. Based on the association of P-95 expression
with decreased accumulation of daunorubicin in AML cells,
however, we feel that P-95 may have a role as a mediator of
anthracycline resistance in some AML cells.
The association of P-95 with decreased dnr retention, as
well as accumulation, and the small modulatory effects of
CsA are more obvious in the MCF-7/AdrVp subline than in
AML blasts. These differences may be due to the difficulties
in comparing a subcloned cell line, made drug resistant in
vitro, with a heterogeneous population of unselected leu-
kaemia cells in a clinical specimen. Immunohistochemical
studies have shown tremendous heterogeneity of P-glyco-
protein and topoisomerase II expression in AML blasts
(Kaufman et al., 1994). It is very likely that AML samples
that are positive for P-95 by Western blotting will still have a
large proportion of cells that do not express the protein.
More convincing evidence for the role of P-95 as a drug
resistance protein will require cloning of the cDNA encoding
P-95 and demonstrating decreased anthracycline accumula-
tion and drug resistance in cells that have been transfected
with the cDNA.
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